Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$7.23 +1.7%	$6.30	$3.93 ▼ $7.54	$364.59M	1.55	710,270 shs	850,820 shs
CAPR Capricor Therapeutics	$7.10 +1.3%	$8.58	$3.98 ▼ $23.40	$320.70M	0.59	1.78 million shs	888,772 shs
FULC Fulcrum Therapeutics	$6.88 +5.5%	$7.11	$2.32 ▼ $9.90	$352.68M	2.47	984,909 shs	362,286 shs
IPA ImmunoPrecise Antibodies	$3.20 +21.7%	$1.70	$0.27 ▼ $3.21	$121.39M	0.49	1.64 million shs	2.99 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	+1.69%	+1.40%	+7.75%	+12.62%	+37.98%
CAPR Capricor Therapeutics	+1.28%	-10.80%	+4.11%	-30.73%	+55.02%
FULC Fulcrum Therapeutics	+5.52%	+0.88%	-13.02%	+6.83%	-27.88%
IPA ImmunoPrecise Antibodies	+21.67%	+60.00%	+75.82%	+474.40%	+259.59%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABEO Abeona Therapeutics	4.44 of 5 stars	3.5	2.0	4.5	2.5	2.5	1.3
CAPR Capricor Therapeutics	3.072 of 5 stars	4.6	2.0	0.0	2.1	0.8	0.6
FULC Fulcrum Therapeutics	0.9836 of 5 stars	2.3	1.0	0.0	2.3	1.7	0.0
IPA ImmunoPrecise Antibodies	1.8251 of 5 stars	2.5	3.0	0.0	3.9	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABEO Abeona Therapeutics	3.00	Buy	$19.50	169.71% Upside
CAPR Capricor Therapeutics	3.11	Buy	$22.56	217.68% Upside
FULC Fulcrum Therapeutics	2.63	Moderate Buy	$7.57	10.05% Upside
IPA ImmunoPrecise Antibodies	3.00	Buy	$4.00	25.00% Upside

Current Analyst Ratings Breakdown

Latest IPA, FULC, ABEO, and CAPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ABEO Abeona Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/15/2025	ABEO Abeona Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$19.00 ➝ $20.00
7/30/2025	FULC Fulcrum Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$4.00 ➝ $5.00
7/29/2025	FULC Fulcrum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $12.00
7/14/2025	CAPR Capricor Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/14/2025	ABEO Abeona Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
7/14/2025	CAPR Capricor Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$31.00 ➝ $12.00
7/11/2025	CAPR Capricor Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$20.00
7/11/2025	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$77.00 ➝ $24.00
6/30/2025	CAPR Capricor Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00
6/26/2025	CAPR Capricor Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABEO Abeona Therapeutics	$3.50M	105.93	N/A	N/A	$3.19 per share	2.27
CAPR Capricor Therapeutics	$22.27M	14.58	N/A	N/A	$2.30 per share	3.09
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
IPA ImmunoPrecise Antibodies	$24.52M	6.02	N/A	N/A	$0.37 per share	8.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABEO Abeona Therapeutics	-$63.73M	$0.70	10.33	N/A	N/A	N/A	89.05%	45.64%	N/A
CAPR Capricor Therapeutics	-$40.47M	-$1.64	N/A	N/A	N/A	-181.71%	-62.71%	-50.82%	N/A
FULC Fulcrum Therapeutics	-$9.73M	-$1.22	N/A	N/A	N/A	N/A	-31.05%	-28.96%	N/A
IPA ImmunoPrecise Antibodies	-$21.69M	-$0.68	N/A	N/A	N/A	-122.10%	-40.62%	-22.19%	9/15/2025 (Estimated)

Latest IPA, FULC, ABEO, and CAPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/15/2025	Q1 2026	IPA ImmunoPrecise Antibodies	-$0.04	N/A	N/A	N/A	$5.90 million	N/A
8/14/2025	Q2 2025	ABEO Abeona Therapeutics	-$0.39	$1.71	+$2.10	$1.71	$21.71 million	$0.40 million
8/11/2025	Q2 2025	CAPR Capricor Therapeutics	-$0.48	-$0.57	-$0.09	-$0.57	$2.60 million	N/A
7/29/2025	Q2 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A
7/29/2025	Q4 2025	IPA ImmunoPrecise Antibodies	-$0.02	-$0.04	-$0.02	-$0.04	$7.89 million	$5.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABEO Abeona Therapeutics	N/A	N/A	N/A	N/A	N/A
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
IPA ImmunoPrecise Antibodies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABEO Abeona Therapeutics	0.09	6.73	4.90
CAPR Capricor Therapeutics	N/A	4.37	4.37
FULC Fulcrum Therapeutics	N/A	24.42	24.42
IPA ImmunoPrecise Antibodies	0.49	2.08	1.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABEO Abeona Therapeutics	80.56%
CAPR Capricor Therapeutics	21.68%
FULC Fulcrum Therapeutics	89.83%
IPA ImmunoPrecise Antibodies	6.70%

Insider Ownership

Company	Insider Ownership
ABEO Abeona Therapeutics	6.90%
CAPR Capricor Therapeutics	10.50%
FULC Fulcrum Therapeutics	7.00%
IPA ImmunoPrecise Antibodies	6.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABEO Abeona Therapeutics	90	51.28 million	47.74 million	Optionable
CAPR Capricor Therapeutics	101	45.72 million	40.92 million	Optionable
FULC Fulcrum Therapeutics	100	54.09 million	50.31 million	Optionable
IPA ImmunoPrecise Antibodies	80	46.15 million	43.00 million	Not Optionable

IPA, FULC, ABEO, and CAPR Headlines

Recent News About These Companies

Short Interest in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Grows By 46.3%

August 21 at 1:08 PM | marketbeat.com

AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe ...

August 6, 2025 | dutchnews.nlD

ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate ...

August 6, 2025 | gurufocus.com

ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate ...

August 6, 2025 | gurufocus.com

ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation

August 6, 2025 | financialpost.comF

Short Interest in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Expands By 114.5%

August 6, 2025 | marketbeat.com

ImmunoPrecise (IPA) Q4 2025 Earnings Transcript

August 4, 2025 | fool.com

HC Wainwright Has Positive Outlook for IPA FY2028 Earnings

August 4, 2025 | marketbeat.com

Wall Street Zen Upgrades ImmunoPrecise Antibodies (NASDAQ:IPA) to "Hold"

August 3, 2025 | marketbeat.com

HC Wainwright Has Negative Outlook of IPA Q1 Earnings

August 2, 2025 | marketbeat.com

ImmunoPrecise Antibodies (NASDAQ:IPA) Issues Earnings Results

July 30, 2025 | marketbeat.com

IPA interactive stock chart | ImmunoPrecise Antibodies Ltd. stock - Yahoo Finance

July 29, 2025 | nz.finance.yahoo.com

ImmunoPrecise Antibodies Reports Record Revenue and Growth

July 29, 2025 | tipranks.com

ImmunoPrecise Antibodies Ltd. (IPA) Reports Q4 Loss, Lags Revenue Estimates

July 29, 2025 | zacks.com

ImmunoPrecise Antibodies Reports Record Fiscal Year 2025 Results

July 29, 2025 | tipranks.com

ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA

July 29, 2025 | businesswire.com

ImmunoPrecise Unveils Breakthrough in Predicting Drug Antibody Risks

July 24, 2025 | tipranks.com

ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic

July 24, 2025 | businesswire.com

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025

July 16, 2025 | businesswire.com

ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement

July 14, 2025 | financialpost.comF

ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement

July 14, 2025 | financialpost.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPA, FULC, ABEO, and CAPR Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

$7.23 +0.12 (+1.69%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$7.21 -0.02 (-0.28%)

As of 08/22/2025 07:53 PM Eastern

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Capricor Therapeutics NASDAQ:CAPR

$7.10 +0.09 (+1.28%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$7.10 0.00 (-0.07%)

As of 08/22/2025 07:58 PM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Fulcrum Therapeutics NASDAQ:FULC

$6.88 +0.36 (+5.52%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$6.88 +0.00 (+0.01%)

As of 08/22/2025 05:10 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

ImmunoPrecise Antibodies NASDAQ:IPA

$3.20 +0.57 (+21.67%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.21 +0.01 (+0.31%)

As of 08/22/2025 07:59 PM Eastern

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time